secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056223
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports Q1 net loss of $44.5M; cash $691.8M; pipeline milestones on track
--------------------------------------------------------------------------------

- Q1 2024 net loss of $44.5M; R&D expense $38.6M, G&A $14.0M.
- Cash, cash equivalents and marketable securities $691.8M as of March 31, 2024; runway into 2027.
- Updated data from ARROS-1 (ROS1) and ALKOVE-1 (ALK) trials expected at a medical meeting in H2 2024.
- Phase 1 trial for HER2 program (NVL-330) expected to initiate in 2024.
- Plans to outline front-line development strategy for ALK program in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024056223/0000950170-24-056223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000095017024056223/nuvl-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer